Dineo Mpanya1, Nqoba Tsabedze2, Carlos Libhaber3, Brenda Kagodora3, Mboyo-Di-Tamba Vangu3. 1. Department of Nuclear Medicine and Molecular Imaging, Faculty of Health Sciences, University of the Witwatersrand, Charlotte Maxeke Johannesburg Academic Hospital and Chris Hani Baragwanath Academic Hospital, Johannesburg, South Africa. Email: Dineo.Mpanya@wits.ac.za. 2. Division of Cardiology, Department of Internal Medicine, Faculty of Health Sciences, University of the Witwatersrand, Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, South Africa. 3. Department of Nuclear Medicine and Molecular Imaging, Faculty of Health Sciences, University of the Witwatersrand, Charlotte Maxeke Johannesburg Academic Hospital and Chris Hani Baragwanath Academic Hospital, Johannesburg, South Africa.
Abstract
BACKGROUND: Positron emission tomography detects patients with myocardial contractile dysfunction secondary to ischaemic heart disease who may benefit from coronary revascularisation. METHODS: We reviewed technetium-99m sestamibi singlephoton emission computed tomography (SPECT) and fluorine-18 fluorodeoxyglucose (F18-FDG) positron emission tomography (PET) data from 236 patients imaged between January 2009 and June 2015. The patients were grouped into three groups: no evidence of viability, viability 1-10% and viability > 10%. RESULTS: Viability exceeding 10% was evident in 55% of the patients. On multivariate analysis, aspirin intake [OR: 1.92; 95% CI: 1.08-3.41; p = 0.026] and hypertension [OR: 1.89; 95% CI: 1.07-3.33; p = 0.029] were clinical factors associated with the presence of myocardial viability. CONCLUSION: Our study demonstrated that F18-FDG PET was able to identify 55% of patients with ischaemic heart disease with viability in more than 10% of the total myocardium when using a 17-segment model.
BACKGROUND: Positron emission tomography detects patients with myocardial contractile dysfunction secondary to ischaemic heart disease who may benefit from coronary revascularisation. METHODS: We reviewed technetium-99m sestamibi singlephoton emission computed tomography (SPECT) and fluorine-18 fluorodeoxyglucose (F18-FDG) positron emission tomography (PET) data from 236 patients imaged between January 2009 and June 2015. The patients were grouped into three groups: no evidence of viability, viability 1-10% and viability > 10%. RESULTS: Viability exceeding 10% was evident in 55% of the patients. On multivariate analysis, aspirin intake [OR: 1.92; 95% CI: 1.08-3.41; p = 0.026] and hypertension [OR: 1.89; 95% CI: 1.07-3.33; p = 0.029] were clinical factors associated with the presence of myocardial viability. CONCLUSION: Our study demonstrated that F18-FDG PET was able to identify 55% of patients with ischaemic heart disease with viability in more than 10% of the total myocardium when using a 17-segment model.
Authors: Arun Abraham; Graham Nichol; Kathryn A Williams; Ann Guo; Robert A deKemp; Linda Garrard; Ross A Davies; Lloyd Duchesne; Haissam Haddad; Benjamin Chow; Jean DaSilva; Rob S B Beanlands Journal: J Nucl Med Date: 2010-03-17 Impact factor: 10.057
Authors: Franz-Josef Neumann; Miguel Sousa-Uva; Anders Ahlsson; Fernando Alfonso; Adrian P Banning; Umberto Benedetto; Robert A Byrne; Jean-Philippe Collet; Volkmar Falk; Stuart J Head; Peter Jüni; Adnan Kastrati; Akos Koller; Steen D Kristensen; Josef Niebauer; Dimitrios J Richter; Petar M Seferovic; Dirk Sibbing; Giulio G Stefanini; Stephan Windecker; Rashmi Yadav; Michael O Zembala Journal: Eur Heart J Date: 2019-01-07 Impact factor: 29.983
Authors: Stephan Windecker; Philippe Kolh; Fernando Alfonso; Jean-Philippe Collet; Jochen Cremer; Volkmar Falk; Gerasimos Filippatos; Christian Hamm; Stuart J Head; Peter Jüni; A Pieter Kappetein; Adnan Kastrati; Juhani Knuuti; Ulf Landmesser; Günther Laufer; Franz-Josef Neumann; Dimitrios J Richter; Patrick Schauerte; Miguel Sousa Uva; Giulio G Stefanini; David Paul Taggart; Lucia Torracca; Marco Valgimigli; William Wijns; Adam Witkowski Journal: EuroIntervention Date: 2015-01 Impact factor: 6.534
Authors: M A Auerbach; H Schöder; C Hoh; S S Gambhir; S Yaghoubi; J W Sayre; D Silverman; M E Phelps; H R Schelbert; J Czernin Journal: Circulation Date: 1999-06-08 Impact factor: 29.690
Authors: Robert O Bonow; Gerald Maurer; Kerry L Lee; Thomas A Holly; Philip F Binkley; Patrice Desvigne-Nickens; Jaroslaw Drozdz; Pedro S Farsky; Arthur M Feldman; Torsten Doenst; Robert E Michler; Daniel S Berman; Jose C Nicolau; Patricia A Pellikka; Krzysztof Wrobel; Nasri Alotti; Federico M Asch; Liliana E Favaloro; Lilin She; Eric J Velazquez; Robert H Jones; Julio A Panza Journal: N Engl J Med Date: 2011-04-04 Impact factor: 91.245
Authors: Gianni D'Egidio; Graham Nichol; Kathryn A Williams; Ann Guo; Linda Garrard; Robert deKemp; Terrence D Ruddy; Jean DaSilva; Dennis Humen; Karen Y Gulenchyn; Michael Freeman; Normand Racine; Francois Benard; Paul Hendry; Rob S B Beanlands Journal: JACC Cardiovasc Imaging Date: 2009-09
Authors: Lee Fong Ling; Thomas H Marwick; Demetrio Roland Flores; Wael A Jaber; Richard C Brunken; Manuel D Cerqueira; Rory Hachamovitch Journal: Circ Cardiovasc Imaging Date: 2013-04-17 Impact factor: 7.792
Authors: A F L Schinkel; J J Bax; F B Sozzi; E Boersma; R Valkema; A Elhendy; J R T C Roelandt; D Poldermans Journal: Heart Date: 2002-08 Impact factor: 5.994